What's in a (drug) name?

The names of the immunotherapy monoclonal antibodies seem like examples of outright butchery of the English language: rituximab, tositumomab, ibritumomab and so on. Can you imagine a less-catchy set of names for drugs than these? They look backwards or like they belong in the Jumble.

But as with all drugs, there is method to the madness. Each name has four parts:

Drug name = prefix + infix(1) + infix(2) + suffix.

Prefix: Meaningless aspect. Just a name.
Infix(1): This part denotes the drug's target in the body.
Infix(2): This part denotes the source of the antibody. Monoclonal antibodies are developed in the lab from sources ranging from mice to primates to more than one source (chimeric).
Suffix: Denotes the fact that it is a monoclonal antibody (mab). All monoclonal antibodies end this way.

Behold:

Tositumomab (Bexxar) = Tosi- + tu(m) + o + mab
Ibritumomab (Zevalin) = Ibri + tu(m) + o + mab
Rituximab (Rituxan) = Ri + tu + xi + mab

In Infix(1), the letters "tu" mean 'miscellaneous tumor'. In Infix(2), the letter "o" means 'mouse', the letters 'xi' mean chimeric.

So, rituximab for example is a chimeric monoclonal antibody that targets miscelleneous tumors.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap